Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

被引：1
|
作者：
Jakubowiak, Andrzej [1 ]
Jasielec, Jagoda [2 ]
Rosenbaum, Cara [3 ]
Orlowski, Robert Z. [4 ]
Cohen, Adam [5 ]
Bensinger, William I. [6 ]
Anderson, Aparna [7 ]
Dossett, Tommy [7 ]
Iskander, Karim [8 ]
Mezzi, Khalid [8 ]
Welliver, Timothy [8 ]
Yusuf, Akeem [8 ]
Durie, Brian [9 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Swedish Canc Inst, Seattle, WA USA
[7] Stat Collaborat Inc, Washington, DC USA
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
carfilzomib; Pomalidomide; relapsed/refractory multiple myeloma;
D O I：
10.1016/j.clml.2019.09.050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-049
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [1] Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis
    Mehta, Pallavi
    Yadav, Neha
    Bhaarat, Mohan
    Mirgh, Sumeet Prakash
    Khushoo, Vishvdeep
    Thekuddan, Shinto Francis
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    BLOOD, 2019, 134
  • [2] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    BLOOD, 2015, 126 (20) : 2284 - 2290
  • [3] Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
    Pallavi Mehta
    Neha Yadav
    Bhaarat Folbs
    Jyotsna Kapoor
    Vishvdeep Khushoo
    Narendra Agrawal
    Rayaz Ahmed
    Dinesh Bhurani
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 264 - 273
  • [4] A PHASE 1-2 STUDY OF CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE
    Bringhen, S.
    Mina, R.
    Liberati, A. M.
    Belotti, A.
    Gaidano, G.
    Bertazzoni, P.
    Stocchi, R.
    Ruggeri, M.
    Ribolla, R.
    Di Sano, C.
    Patriarca, F.
    Bernardini, A.
    De Paoli, L.
    Cafro, A. M.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 25 - 25
  • [5] Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India
    Mehta, Pallavi
    Yadav, Neha
    Folbs, Bhaarat
    Kapoor, Jyotsna
    Khushoo, Vishvdeep
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 264 - 273
  • [6] Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
    Landgren, Ola
    Kazandjian, Dickran
    Roussel, Murielle
    Jasielec, Jagoda
    Dytfeld, Dominik
    Anderson, Aparna
    Kervin, Tara A.
    Iskander, Karim
    McFadden, Ian
    Jakubowiak, Andrzej J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2413 - 2421
  • [7] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
    Yashar, David
    Spektor, Tanya M.
    Martinez, Daisy
    Ghermezi, Matthew
    Swift, Regina A.
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    Berenson, James R.
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
  • [8] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
  • [9] Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies
    Landgren, Ola
    Attal, Michel
    Kazandjian, Dickran
    Roussel, Murielle
    Jasielec, Jagoda K.
    Dytfeld, Dominik
    Anderson, Aparna
    Kervin, Tara
    Iskander, Karim
    Mezzi, Khalid
    Welliver, Tim
    Yusuf, Akeem
    Jakubowiak, Andrzej
    BLOOD, 2019, 134
  • [10] Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
    Gueneau, Pauline
    Chretien, Marie-Lorraine
    Cransac-Miet, Amelie
    Aho, Ludwig Serge
    Lafon, Ingrid
    Favennec, Camille
    Guy, Julien
    Caillot, Denis
    Boulin, Mathieu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 518 - 525
12345